What does agenus Inc do?

Company Information Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer.

When was agenus created?

March 31, 1994
Agenus/Founded

What drugs does agenus make?

• Balstilimab (AGEN2034) PD-1.
• Zalifrelimab (AGEN1884) CTLA-4.
• AGEN1181. Multipurpose, second-generation.
• TIGIT. Agenus fully-owned.
• AGEN1571. Tumor-associated macrophage.
• Cytokine (bispecific) Agenus fully-owned.
• Stromal Conditioning (bispecific) Agenus fully-owned.
• TME conditioning (bispecific) Agenus fully-owned.

Who makes Balstilimab?

(NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus’ Biologics …

Who is Agenus and what do they do?

LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) — Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonstrating the

What makes Agenus a good company to invest in?

Agenus’ broad portfolio of novel checkpoint and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. The Company has formed collaborations with Merck and Incyte to discover and develop multiple checkpoint antibodies.

Who is the vice president of Regulatory Affairs for Agenus?

Dr. Marc Wiles serves as Agenus’ Vice President of Regulatory Affairs. He heads both our US and international regulatory efforts, and is Agenus’ resident nonclinical development expert, with a focus in toxicology.

How is the Agenus OX40 antibody program funded?

Our INCAGN1949 antibody targeting OX40 is part of our global alliance with Incyte. The program is funded by Incyte with Agenus eligible for potential milestones and 15% royalties, subject to reduction for certain third party obligations. INCAGN1949 is currently in Phase 1 / 2 clinical trials ( www.clinicaltrials.gov ).